The Value of Phenotypic Precision Medicine in Prostate Cancer.
Nathan M HawkeyAmanda BroderickDaniel J GeorgeOliver SartorAndrew J ArmstrongPublished in: The oncologist (2022)
Prostate cancer is the most common cancer among men and the second leading cause of cancer-related death. For patients who develop metastatic disease, tissue-based and circulating-tumor-based molecular and genomic biomarkers have emerged as a means of improving outcomes through the application of precision medicine. However, the benefit is limited to a minority of patients. An additional approach to further characterize the biology of advanced prostate cancer is through the use of phenotypic precision medicine, or the identification and targeting of phenotypic features of an individual patient's cancer. In this review article, we will discuss the background, potential clinical benefits, and limitations of genomic and phenotypic precision medicine in prostate cancer. We will also highlight how the emergence of image-based phenotypic medicine may lead to greater characterization of advanced prostate cancer disease burden and more individualized treatment approaches in patients.
Keyphrases
- prostate cancer
- radical prostatectomy
- end stage renal disease
- ejection fraction
- newly diagnosed
- peritoneal dialysis
- papillary thyroid
- small cell lung cancer
- circulating tumor
- deep learning
- adipose tissue
- drug delivery
- copy number
- circulating tumor cells
- risk assessment
- metabolic syndrome
- case report
- insulin resistance
- patient reported
- lymph node metastasis